Essential Pharma has completed two individual transactions with UK-based oral liquid medicines manufacturer Rosemont Pharmaceuticals.
The company has closed the sale of its oral liquid portfolio to Rosemont.
In a separate transaction, it has acquired a range of niche products from Rosemont, which are poised to support its geographic expansion.
With the divestments of UK oral liquid products, Essential Pharma aims to streamline its portfolio and advance its international growth strategy.
Essential Pharma CEO Steen Vangsgaard said: “The Rosemont products bring additional niche products into our portfolio with international expansion potential.
“The divestiture of our UK oral liquid products streamlines our portfolio, allowing us to focus and accelerate our strategic growth ambition of building a leading international speciality pharma platform.”
Rosemont Pharmaceuticals chief executive officer Howard Taylor said: “These transactions support Rosemont’s strategy to be a rapid developer, reliable manufacturer and global supplier of patient-focused medicines by focusing our current portfolio and expanding the number of products we can supply to patients.”
Under the divestment, Rosemont obtained licences, registrations and trademarks, along with related commercial rights to a portfolio of oral generic products.
Essential is a speciality pharmaceutical firm, dedicated to providing patients with access to ‘at-risk’ products across several therapeutic areas.
With operations in more than 20 countries, it supplies more than 150 essential medicines across multiple therapeutic areas. It has eight manufacturing sites across the EU and US.
Essential Pharma is supported by Gyrus Capital, an investment firm focused on sectors with long term sustainable growth, including healthcare.
Established in 1967, Rosemont Pharmaceuticals provides a range of prescription medicines, comprising more than 130 oral liquid medicines, including 70 licensed products.
The company was acquired by Inflexion Private Equity Partners in June 2020.
